[Alendronate in postmenopausal women with osteopenia and osteoporosis: effects on bone mineral density during treatment and after withdrawal]

Zhonghua Yi Xue Za Zhi. 2002 Sep 25;82(18):1254-6.
[Article in Chinese]

Abstract

Objective: To determine the efficacy of alendronate (Fosamax) administration and withdrawal on the bone mineral density (BMD) in postmenopausal women with osteopenia and osteoporosis.

Methods: Alendronate (10 mg) and calcium carbonate (containing calcium 500 mg) were administered daily to 25 Chinese menopausal women with osteopenia and osteoporosis for 6 months and to 15 women for 12 months. After the withdrawal of alendronate, calcium carbonate was administered continuously. Follow-up was made three times for the 6-month group: before treatment, 6 months after treatment, and 13 +/- 4 months (6 - 24 months) after aldoronate withdrawal, and was made four times for the 12-month group: before treatment, 6 months and 12 months after treatment, and 23 +/- 7 months (14 - 36 months) after alendronate withdrawal to determine the BMD of lumbar spine 2 approximately 4, neck of femur, Wards triangle, and greater trochanter and blood alkaline phosphatase (ALP).

Results: Compared to the baseline value, the BMD in lumbar spine and hip increased significantly 6 months after treatment in 6-month group, with the BMD in lumbar spine 2 - 4 increased by 5.3% (P < 0.001). In the 6 month group, no significant decline was found in the BMD in lumbar spine and hip 13 +/- 4 months after alendronate withdrawal, the BMD in greater trochanter even increased further compared with that 6 months after treatment. In the 12-month group, the BMD significantly increased except in the Wards triangle after 6 months' treatment with an increase by 4.2% in lumbar spine 2 - 4 (P < 0.001). After 12 months' treatment the increment of BMD in lumbar spine 2 - 4 was 6.1% (P < 0.001) and the BMD of the hip remained unchanged. 23 +/- 7 months after the alendronte withdrawal the values of BMD in lumbar spine and hip were almost the same as that 12 months after treatment.

Conclusion: Alendronate increases the BMD in spine and hip, especially in lumbar spine. The skeletal benefits are maintained for at least 13 - 23 months in spine and hip after withdrawal of alendrenate.

Publication types

  • Clinical Trial
  • English Abstract

MeSH terms

  • Aged
  • Alendronate / therapeutic use*
  • Alkaline Phosphatase / blood
  • Alkaline Phosphatase / drug effects
  • Bone Density / drug effects*
  • Bone Diseases, Metabolic / drug therapy*
  • Calcium Carbonate / therapeutic use
  • Double-Blind Method
  • Female
  • Follow-Up Studies
  • Hip Joint / drug effects
  • Humans
  • Lumbar Vertebrae / drug effects
  • Middle Aged
  • Osteoporosis, Postmenopausal / drug therapy*
  • Time Factors
  • Treatment Outcome

Substances

  • Alkaline Phosphatase
  • Calcium Carbonate
  • Alendronate